Artivion closes Endospan buyout to acquire recently approved heart device

Artivion closes Endospan buyout to acquire recently approved heart device is a pharma and life sciences industry update from MedTech Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Nick Paul Taylor · 2026-05-19

Artivion is targeting a $150 million annual U.S. market for the Nexus Aortic Arch System.

Source: MedTech Dive